All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here
DelveInsight’s ” Limb Girdle Muscular Dystrophy Market Insights, Epidemiology, and Market Forecast – 2034″ report delivers an in-depth understanding of Limb Girdle Muscular Dystrophy, historical and forecasted epidemiology, as well as the Limb Girdle Muscular Dystrophy Market trends in the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan.
Discover Key Insights into the Limb Girdle Muscular Dystrophy Market with DelveInsight’s In-Depth Report @ Limb Girdle Muscular Dystrophy Treatment Market Size
Key Takeaways from the Limb Girdle Muscular Dystrophy Market Report
* On October 27, 2025 (Monday), BridgeBio Pharma Inc. announced positive topline results from its Phase 3 FORTIFY study evaluating BBP-418 in patients with Limb-Girdle Muscular Dystrophy type 2I/R9 (LGMD2I/R9), as reported by Nasdaq (via RTTNews). The trial successfully met all primary and secondary endpoints, showing a 1.8-fold increase in glycosylated DG at three months, which was sustained through 12 months. It also demonstrated an 82% reduction in serum creatine kinase levels compared to placebo. Patients exhibited clinically meaningful improvements in functional outcomes, including a 0.14 m/s gain from baseline and 0.27 m/s versus placebo in the 100-meter timed test. Moreover, forced vital capacity improved by approximately 3% from baseline and 5% versus placebo.
* On 06 October 2025, Atamyo Therapeutics announced a ATA-003-GSAR study is to evaluate the safety and tolerability of a single intravenous infusion of ATA-200 in pediatric patients with limb girdle muscular dystrophy type 2c/R5 (LGMD R5). Patients will be treated sequentially in 2 dose-cohorts.
* On 06 October 2025, AskBio Inc. conducted a study is to evaluate the safety and tolerability of a single intravenous infusion of AB-1003 in adults diagnosed with limb girdle muscular dystrophy type 2I/R9 (LGMD2I/R9). Participants will be treated in sequential, dose-level cohorts. (Part 1)
* According to DelveInsight’s estimates, the total prevalent cases of Limb Girdle Muscular Dystrophy affects males and females in equal numbers. The prevalence of Limb Girdle Muscular Dystrophy is unknown, but estimates range from one in 14,500 to one in 123,000 and is expected to rise during the study period [2020-2034]. Estimates show the highest prevalent cases of Limb Girdle Muscular Dystrophy is in the United States followed by Europe.
* According to the findings, the age of onset can vary greatly even among individuals of the same family. The relative frequencies of the different types of LGMD vary from case to case, but worldwide LGMD2G, 2H and 2J are extremely rare.
* As per DelveInsight’s estimates, LGMD prevalence across Europe ranges from 0.8 to 6 per 100,000.
* According to the findings, in the UK, dominantly inherited LGMD is less common and reported to be only 5-10% of all LGMD. It is also suggested that within the population of Northern England, LGMD accounts for 6.2% of all neuromuscular patients.
* The leading Limb Girdle Muscular Dystrophy Companies such as ML Bio Solutions, Asklepios BioPharmaceutical, Sarepta Therapeutics, Inc., Atamyo Therapeutics, Edgewise Therapeutics, Vita Therapeutics, BridgeBio Pharma, Hansa Biopharma, and others.
* Promising Limb Girdle Muscular Dystrophy Therapies such as SRP-9005, Corticosteroid, SRP-9003, Glucocorticoid, Deflazacort, ATYR1940, Prednisone, and others.
Stay ahead in the Limb Girdle Muscular Dystrophy Therapeutics Market with DelveInsight’s Strategic Report @ Limb Girdle Muscular Dystrophy Market Outlook
Limb Girdle Muscular Dystrophy Epidemiology Segmentation
* Total Limb Girdle Muscular Dystrophy Prevalent Cases
* Limb Girdle Muscular Dystrophy Type-specific Prevalent Cases
* Limb Girdle Muscular Dystrophy Subtype-specific Prevalent Cases
* Limb Girdle Muscular Dystrophy Diagnosed and Treatable Cases
Download the report to understand which factors are driving Limb Girdle Muscular Dystrophy Epidemiology trends @ Limb Girdle Muscular Dystrophy Prevalence
Limb Girdle Muscular Dystrophy Emerging Drugs
* BBP-418: Bridge Bio
BridgeBio is pioneering an oral therapy, BBP-418, for limb girdle muscular dystrophy type 2I/R9 (LGMD2I/R9). This treatment targets the dysfunctional alpha-dystroglycan protein, addressing the underlying cause of muscle weakness. The Phase II data shows potential for functional improvements and reduced muscle breakdown. BBP-418 has received Fast Track and Orphan Drug designations from FDA and is currently in Phase III clinical trials.
* SRP-9003: Sarepta Therapeutics
Sarepta Therapeutics is actively involved in the development of gene therapies for Limb-Girdle Muscular Dystrophy (LGMD). The company has multiple LGMD gene therapy programs in progress, including LGMD2E/R4, LGMD2D, LGMD2C, LGMD2B, LGMD2L, and LGMD2A, collectively addressing over 70% of known LGMD cases.
* AB-1003 (LION-101): Asklepios Biopharmaceuticals/ Ask Bio
Asklepios Biopharmaceuticals’ LION-101 is a cutting-edge therapy designed to combat LGMD by delivering a functional version of the FKRP gene to the body’s cells. This innovative approach utilizes a recombinant adeno-associated virus, a viral vector known for its safety and ease of manipulation in laboratory settings. AB-1003 has secured Investigational New Drug (IND) clearance and Fast Track designation from the US FDA. It is currently advancing through Phase I/II clinical trials.
Limb Girdle Muscular Dystrophy Market Outlook
Major Limb Girdle Muscular Dystrophy Companies such as Bridge Bio, Sarepta Therapeutics, and Asklepios Biopharmaceuticals are evaluating their lead candidates in different stages of clinical development, respectively. They aim to investigate their products for the treatment of Limb Girdle Muscular Dystrophy (LGMD). The Limb Girdle Muscular Dystrophy Market Size in the seven major markets is expected to increase substantially from 2024.
Get In-Depth Knowledge on Limb Girdle Muscular Dystrophy Market Trends and Forecasts with DelveInsight @ Limb Girdle Muscular Dystrophy Therapeutics Market Size
Limb Girdle Muscular Dystrophy Companies
ML Bio Solutions, Asklepios BioPharmaceutical, Sarepta Therapeutics, Inc., Atamyo Therapeutics, Edgewise Therapeutics, Vita Therapeutics, BridgeBio Pharma, Hansa Biopharma, and others.
Scope of the Limb Girdle Muscular Dystrophy Market Report
* Coverage- 7MM
* Forecast Period- 2024-2034
* Limb Girdle Muscular Dystrophy Companies- ML Bio Solutions, Asklepios BioPharmaceutical, Sarepta Therapeutics, Inc., Atamyo Therapeutics, Edgewise Therapeutics, Vita Therapeutics, BridgeBio Pharma, Hansa Biopharma, and others.
* Limb Girdle Muscular Dystrophy Therapies- SRP-9005, Corticosteroid, SRP-9003, Glucocorticoid, Deflazacort, ATYR1940, Prednisone, and others.
Unlock Strategic Insights with DelveInsight’s Comprehensive Limb Girdle Muscular Dystrophy Market Report @ Limb Girdle Muscular Dystrophy Market Drivers and Barriers
Table of Contents
1 Key Insights
2 Limb Girdle Muscular Dystrophy Market Report Introduction
3 Limb Girdle Muscular Dystrophy Executive Summary
4 Limb Girdle Muscular Dystrophy Key Events
5 Limb Girdle Muscular Dystrophy Epidemiology and Market Forecast Methodology
6 Limb Girdle Muscular Dystrophy (LGMD) Market Overview at a Glance
7 Limb Girdle Muscular Dystrophy Disease Background and Overview
8 Limb Girdle Muscular Dystrophy Diagnostic Algorithm
9 Limb Girdle Muscular Dystrophy Epidemiology and Patient Cases: 7MM
10. Limb Girdle Muscular Dystrophy Treatment
11. Limb Girdle Muscular Dystrophy Patient Journey
12. Limb Girdle Muscular Dystrophy Unmet Needs
13. Limb Girdle Muscular Dystrophy Emerging Drugs
14 Limb Girdle Muscular Dystrophy:7 Major Market Analysis
15 Limb Girdle Muscular Dystrophy KOL Views
16 Limb Girdle Muscular Dystrophy SWOT Analysis
17 Appendix
18 DelveInsight Capabilities
19 Disclaimer
20 About DelveInsight
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/limb-girdle-muscular-dystrophy-lgmd-market
Press Release Distributed by ABNewswire.com
To view the original version on ABNewswire visit: Limb Girdle Muscular Dystrophy Therapeutics Market Size in the 7MM is expected to increase substantially by 2034, estimates DelveInsight
